GlobalData on MSN
Tandem secures FDA approval for Control-IQ+ use in pregnancy
The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.
Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...
The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results